Recurrent Melanoma Completed Phase 1 Trials for DB00526 (Oxaliplatin)

IndicationStatusPhase
DBCOND0028662 (Recurrent Melanoma)Completed1
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT00101270Oxaliplatin and Irinotecan in Treating Young Patients With Refractory Solid Tumors or LymphomasTreatment